Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis, Bayer CropScience, Monsanto, and Cargill Launch Crop Genomics Project

NEW YORK, Dec. 23--Agrinomics, the joint venture between Exelixis and Crop Science, has launched a crop genomics collaboration with Renessen, the joint venture between Monsanto and Cargill, the companies announced on Dec. 19.

 

The two companies will partner to improve seed oil crops. Agrinomics will apply its functional genomics expertise, including gene screening and phenotypic identification. Renessen will direct development and commercialization.

 

In the deal, Agrinomics will receive research funding, pre-commercial milestone payments, and royalties on any commercialized products from Renessen. Renessen will also direct the development of transgenic strains.

 

Agrinomics, launched in 1999, has developed a gene discovery platform based on Arabidopsis gene expression.

 

Canola and soybeans are the major oil seed crops, accounting for more than 70 percent of the $32 billion global market, according to the companies.

 

For further information, see the statement.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.